HypoResolveWithin the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society - among which SIB's Vital-IT Group and the University of Lausanne - have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia, a common and serious complication of diabetes.
This project is supported by the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines.

Read the international press release (EN)